Literature DB >> 20380951

Nonacute coronary syndrome anginal chest pain.

Megha Agarwal1, Puja K Mehta, C Noel Bairey Merz.   

Abstract

Anginal chest pain is one of the most common complaints in the outpatient setting. While much of the focus has been on identifying obstructive atherosclerotic coronary artery disease (CAD) as the cause of anginal chest pain, it is clear that microvascular coronary dysfunction (MCD) can also cause anginal chest pain as a manifestation of ischemic heart disease, and carries an increased cardiovascular risk. Epicardial coronary vasospasm, aortic stenosis, left ventricular hypertrophy, congenital coronary anomalies, mitral valve prolapse, and abnormal cardiac nociception can also present as angina of cardiac origin. For nonacute coronary syndrome (ACS) stable chest pain, exercise treadmill testing (ETT) remains the primary tool for diagnosis of ischemia and cardiac risk stratification; however, in certain subsets of patients, such as women, ETT has a lower sensitivity and specificity for identifying obstructive CAD. When combined with an imaging modality, such as nuclear perfusion or echocardiography testing, the sensitivity and specificity of stress testing for detection of obstructive CAD improves significantly. Advancements in stress cardiac magnetic resonance imaging enables detection of perfusion abnormalities in a specific coronary artery territory, as well as subendocardial ischemia associated with MCD. Coronary computed tomography angiography enables visual assessment of obstructive CAD, albeit with a higher radiation dose. Invasive coronary angiography remains the gold standard for diagnosis and treatment of obstructive lesions that cause medically refractory stable angina. Furthermore, in patients with normal coronary angiograms, the addition of coronary reactivity testing can help diagnose endothelial-dependent and -independent microvascular dysfunction. Lifestyle modification and pharmacologic intervention remains the cornerstone of therapy to reduce morbidity and mortality in patients with stable angina. This review focuses on the pathophysiology, diagnosis, and treatment of stable, non-ACS anginal chest pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380951      PMCID: PMC2876979          DOI: 10.1016/j.mcna.2010.01.008

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  86 in total

Review 1.  Positron emission tomography and molecular imaging.

Authors:  J Knuuti; F M Bengel
Journal:  Heart       Date:  2008-03       Impact factor: 5.994

Review 2.  Cardiac positron emission tomography.

Authors:  Frank M Bengel; Takahiro Higuchi; Mehrbod S Javadi; Riikka Lautamäki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction.

Authors:  Sherif A Sakr; Tarek M Abbas; Maged Z Amer; Eid M Dawood; Nader El-Shahat; Ibraheim A Abdel Aal; Mahmoud M Ramadan
Journal:  Int Heart J       Date:  2009-07       Impact factor: 1.862

4.  Persistent chest pain and no obstructive coronary artery disease.

Authors:  Anita Phan; Chrisandra Shufelt; C Noel Bairey Merz
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

5.  Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.

Authors:  Sean R Wilson; Benjamin M Scirica; Eugene Braunwald; Sabina A Murphy; Ewa Karwatowska-Prokopczuk; Jacqueline L Buros; Bernard R Chaitman; David A Morrow
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

6.  Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.

Authors:  Chiara Melloni; L Kristin Newby
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-01

7.  Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis.

Authors:  Frank Weidemann; Sebastian Herrmann; Stefan Störk; Markus Niemann; Stefan Frantz; Volkmar Lange; Meinrad Beer; Stefan Gattenlöhner; Wolfram Voelker; Georg Ertl; Jörg M Strotmann
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

8.  Increased peripheral circulating inflammatory cells and plasma inflammatory markers in patients with variant angina.

Authors:  Jian-Jun Li; Yu-Ping Zhang; Ping Yang; He-Song Zeng; Xue-Wen Qian; Chao-Yang Zhang; Chen-Gang Zhu; Jie Li; Jin-Long Nan
Journal:  Coron Artery Dis       Date:  2008-08       Impact factor: 1.439

Review 9.  The pathophysiology of chronic ischemic heart disease.

Authors:  Carl J Pepine; Wilmer W Nichols
Journal:  Clin Cardiol       Date:  2007-02       Impact factor: 2.882

Review 10.  Validity of electron beam computed tomography for coronary artery disease: asystematic review and meta-analysis.

Authors:  Nandini Dendukuri; Keith Chiu; James M Brophy
Journal:  BMC Med       Date:  2007-11-25       Impact factor: 8.775

View more
  1 in total

1.  Influence of symptom typicality for predicting MACE in patients without obstructive coronary artery disease: From the CONFIRM Registry (Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry).

Authors:  Ji Hyun Lee; Donghee Han; Bríain Ó Hartaigh; Heidi Gransar; Yao Lu; Asim Rizvi; Mahn Won Park; Hadi Mirhedayati Roudsari; Wijnand J Stuijfzand; Daniel S Berman; Tracy Q Callister; Augustin DeLago; Martin Hadamitzky; Joerg Hausleiter; Mouaz H Al-Mallah; Matthew J Budoff; Philipp A Kaufmann; Gilbert Raff; Kavitha Chinnaiyan; Filippo Cademartiri; Erica Maffei; Todd C Villines; Yong-Jin Kim; Jonathon Leipsic; Gudrun Feuchtner; Gianluca Pontone; Daniele Andreini; Hugo Marques; Ronen Rubinshtein; Stephan Achenbach; Leslee J Shaw; Hyuk-Jae Chang; Jeroen Bax; Benjamin Chow; Ricardo C Cury; Millie Gomez; Erica C Jones; Fay Y Lin; James K Min; Jessica M Peña
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.